Viking Therapeutics, Inc. (VKTX)の価格はいくらですか

Viking Therapeutics, Inc. (VKTX)の価格は$34.24です

Viking Therapeutics, Inc. (VKTX)の時価総額は何ですか

Viking Therapeutics, Inc. (VKTX)の時価総額は$3.99Bです

Viking Therapeutics, Inc.（VKTX）PBR（株価純資産倍率）

Viking Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation of novel treatments for metabolic and endocrine conditions. The company's leading investigational drug, VK2809, is an orally administered, tissue and receptor-selective agonist of the thyroid hormone receptor beta (TRß). This compound is currently progressing through Phase IIb clinical trials, targeting both non-alcoholic steatohepatitis (NASH) in biopsy-confirmed patients and non-alcoholic fatty liver disease (NAFLD). Viking's pipeline also features VK5211, an oral, non-steroidal selective androgen receptor modulator undergoing Phase II studies for individuals recuperating from non-elective hip fracture surgery. Additionally, VK0612, an oral drug candidate for type 2 diabetes, is poised to enter Phase IIb trials. The firm is also developing VK0214, another orally active, tissue and receptor-selective TRß agonist, specifically aimed at X-linked adrenoleukodystrophy. Founded in 2012, Viking Therapeutics is headquartered in San Diego, California.

年	P/B比率	変化
提供された日付のデータは十分ではありません。

年

P/B比率

変化

提供された日付のデータは十分ではありません。

企業	P/B比率	P/B比率の差	国
Vertex Pharmaceuticals Incorporated VRTX.US	6.3419	-	US
Argenx SE ARGX.US	6.2413	-	NL
Moderna, Inc. MRNA.US	3.7087	-	US
CSL Limited CSL.AX	2.5054	-	AU
Lonza Group AG LONN.SW	-	-	CH

企業

P/B比率

P/B比率の差

国